Skip to main content
Erschienen in: PharmacoEconomics 8/2001

01.08.2001 | Leading Article

Pharmacoeconomic Fellowships

The Need for Outcome Measures

verfasst von: Vittorio Maio, Tammy K. Girts, Dr Jennifer H. Lofland, David B. Nash

Erschienen in: PharmacoEconomics | Ausgabe 8/2001

Einloggen, um Zugang zu erhalten

Abstract

Pharmacoeconomic fellowship programmes have been in existence for more than 10 years, but their effectiveness has not been evaluated. The aim of this project was to construct a framework to examine the potential outcome measures for pharmacoeconomic fellowships so that the effectiveness of these programmes may be determined. Using the Donabedian model, the structures, processes, and outcomes of pharmacoeconomic fellowship programmes were investigated. The structures of these programmes include the facilities, qualifications of the teaching staff and organisation, and operations of the institution. Most pharmacoeconomic fellowships are based in academic institutions and the pharmaceutical industry. Credentials of the preceptors and teaching staff consist of an advanced degree and relevant expertise in pharmacoeconomics and outcomes research. The processes of pharmacoeconomic fellowships include the duration of the programme as well as the research skills and the educational components taught. However, current guidelines do not define outcome measures for these pharmacoeconomic fellowships. Potential outcomes may include whether or not a degree was obtained, the management and research skills acquired, as well as the type of experiential training received. Further research is required to develop these outcome measures, so the effectiveness of pharmacoeconomic fellowship programmes may be assessed.
Literatur
1.
Zurück zum Zitat Pritchard C. Trends in economic evaluation: OHE briefing No. 36. London, England. Office of Health Economics, 1998 Pritchard C. Trends in economic evaluation: OHE briefing No. 36. London, England. Office of Health Economics, 1998
2.
Zurück zum Zitat Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther 1998; 20 (6): 1194–202PubMedCrossRef Mullins CD, Ogilvie S. Emerging standardization in pharmacoeconomics. Clin Ther 1998; 20 (6): 1194–202PubMedCrossRef
3.
Zurück zum Zitat St. Jean AD, Landis NT. The pharmacoeconomist: an emerging specialist in health care institutions. Am J Hosp Pharm 1993; 50: 1062–9PubMed St. Jean AD, Landis NT. The pharmacoeconomist: an emerging specialist in health care institutions. Am J Hosp Pharm 1993; 50: 1062–9PubMed
4.
Zurück zum Zitat Motheral BR, Grizzle AJ, Armstrong EP, et al. Role of pharmacoeconomics on drug benefit decision-making: results of a survey. Formulary May 2000; 35: 412–21 Motheral BR, Grizzle AJ, Armstrong EP, et al. Role of pharmacoeconomics on drug benefit decision-making: results of a survey. Formulary May 2000; 35: 412–21
5.
Zurück zum Zitat Knapp KK, Blalock SJ, O’Malley CH. ASHP survey of ambulatory care responsibilities of pharmacists in managed care and integrated health systems 1999. Am J Health Syst Pharm 1999; 56 (23): 2431–43PubMed Knapp KK, Blalock SJ, O’Malley CH. ASHP survey of ambulatory care responsibilities of pharmacists in managed care and integrated health systems 1999. Am J Health Syst Pharm 1999; 56 (23): 2431–43PubMed
6.
Zurück zum Zitat Draugalis JR, Coons SJ. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report. Clin Ther 1994; 16 (3): 523–37PubMed Draugalis JR, Coons SJ. The role of colleges of pharmacy in meeting the pharmacoeconomic needs of the pharmaceutical industry: a conference report. Clin Ther 1994; 16 (3): 523–37PubMed
7.
Zurück zum Zitat Gregor KJ, Draugalis JR. Graduate pharmacoeconomic education and training programs in US colleges of pharmacy. Am J Pharm Educ 1994; 58: 378–81 Gregor KJ, Draugalis JR. Graduate pharmacoeconomic education and training programs in US colleges of pharmacy. Am J Pharm Educ 1994; 58: 378–81
8.
Zurück zum Zitat Cooke J, Godman B, Giles-Burness D. Pharmacoeconomics teaching in the North West Region. Pharm J 1994; 252: 864–6 Cooke J, Godman B, Giles-Burness D. Pharmacoeconomics teaching in the North West Region. Pharm J 1994; 252: 864–6
9.
Zurück zum Zitat Lee J, Lawrence BJ, Sullivan SD, et al. Guidelines for pharmacoeconomic research fellowship. Pharmacotherapy 1999; 19 (9): 1105–9CrossRef Lee J, Lawrence BJ, Sullivan SD, et al. Guidelines for pharmacoeconomic research fellowship. Pharmacotherapy 1999; 19 (9): 1105–9CrossRef
10.
Zurück zum Zitat International Society for Pharmacoeconomics and Outcomes Research. ISPOR directory of fellowships in pharmacoeconomics, health economics, outcomes research or related field of study. Available from: URL: http://www.ispor.org.fellowships.html [Accessed 2000 Jul 10] International Society for Pharmacoeconomics and Outcomes Research. ISPOR directory of fellowships in pharmacoeconomics, health economics, outcomes research or related field of study. Available from: URL: http://​www.​ispor.​org.​fellowships.​html [Accessed 2000 Jul 10]
11.
Zurück zum Zitat American College of Clinical Pharmacy, editor. Directory of Residencies and Fellowships 2000. Kansas City, (MO): American College of Clinical Pharmacy, 2000 American College of Clinical Pharmacy, editor. Directory of Residencies and Fellowships 2000. Kansas City, (MO): American College of Clinical Pharmacy, 2000
12.
Zurück zum Zitat American Society of Health-System Pharmacists. Definitions of pharmacy residencies and fellowships. Am J Hosp Pharm 1987; 44: 1142–4 American Society of Health-System Pharmacists. Definitions of pharmacy residencies and fellowships. Am J Hosp Pharm 1987; 44: 1142–4
13.
Zurück zum Zitat Udvarhelyi IS, Colditz GA, Rai A, et al. Cost effectiveness and cost benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238–44PubMed Udvarhelyi IS, Colditz GA, Rai A, et al. Cost effectiveness and cost benefit analyses in the medical literature. Ann Intern Med 1992; 116: 238–44PubMed
14.
Zurück zum Zitat Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116–21PubMedCrossRef Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. JAMA 2000; 283 (16): 2116–21PubMedCrossRef
15.
Zurück zum Zitat Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. Pharmacoeconomics 2000; 18 (1): 55–62PubMedCrossRef Anis AH, Gagnon Y. Using economic evaluations to make formulary coverage decisions. Pharmacoeconomics 2000; 18 (1): 55–62PubMedCrossRef
16.
Zurück zum Zitat Lee JT, Sanchez LA. Interpretation of ‘cost-effective’ and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622–7PubMed Lee JT, Sanchez LA. Interpretation of ‘cost-effective’ and soundness of economic evaluations in the pharmacy literature. Am J Hosp Pharm 1991; 48: 2622–7PubMed
17.
Zurück zum Zitat Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5PubMedCrossRef Hillman AL, Eisenberg JM, Pauly MV, et al. Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. N Engl J Med 1991; 324: 1362–5PubMedCrossRef
18.
Zurück zum Zitat Drummond R, Harold SL. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000; 283 (16): 2158–60CrossRef Drummond R, Harold SL. Pharmacoeconomic analyses: making them transparent, making them credible. JAMA 2000; 283 (16): 2158–60CrossRef
19.
20.
Zurück zum Zitat Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA 1999; 282 (15): 1474–5PubMedCrossRef Krimsky S. Conflict of interest and cost-effectiveness analysis. JAMA 1999; 282 (15): 1474–5PubMedCrossRef
21.
Zurück zum Zitat Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44 (3): 166–206PubMedCrossRef Donabedian A. Evaluating the quality of medical care. Milbank Mem Fund Q 1966; 44 (3): 166–206PubMedCrossRef
24.
Zurück zum Zitat Pharmacoeconomic and Outcomes Research Fellowship Standards. The Office of Health Policy and Clinical Outcomes, Thomas Jefferson University. Jun 2000: 8 (Data on file) Pharmacoeconomic and Outcomes Research Fellowship Standards. The Office of Health Policy and Clinical Outcomes, Thomas Jefferson University. Jun 2000: 8 (Data on file)
25.
Zurück zum Zitat Standards for fellowship training in pharmacoeconomics and outcomes research. ISPOR position statement. May 1998: 6 (Data on file) Standards for fellowship training in pharmacoeconomics and outcomes research. ISPOR position statement. May 1998: 6 (Data on file)
28.
Zurück zum Zitat Center for Evaluation of Medicines. Workshops calendar: designing and implementing economic evaluation of medicines. Available from: URL: http://www.thecem.net [Accessed 2000 Jul 12] Center for Evaluation of Medicines. Workshops calendar: designing and implementing economic evaluation of medicines. Available from: URL: http://​www.​thecem.​net [Accessed 2000 Jul 12]
30.
Zurück zum Zitat Lloyd KB, Lee JT, Strassels S. The relative effects of fellowship training on career path, job satisfaction and burnout, and quality of life. Pharmacotherapy 1998; 28: 430 Lloyd KB, Lee JT, Strassels S. The relative effects of fellowship training on career path, job satisfaction and burnout, and quality of life. Pharmacotherapy 1998; 28: 430
31.
Zurück zum Zitat Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Committee on Quality of Healthcare in America, Institute of Medicine. Washington DC: National Academy Press, 2000 Kohn LT, Corrigan JM, Donaldson MS, editors. To err is human: building a safer health system. Committee on Quality of Healthcare in America, Institute of Medicine. Washington DC: National Academy Press, 2000
Metadaten
Titel
Pharmacoeconomic Fellowships
The Need for Outcome Measures
verfasst von
Vittorio Maio
Tammy K. Girts
Dr Jennifer H. Lofland
David B. Nash
Publikationsdatum
01.08.2001
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 8/2001
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200119080-00001

Weitere Artikel der Ausgabe 8/2001

PharmacoEconomics 8/2001 Zur Ausgabe